查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1860232

疱疹标记检测市场：按检测类型、技术、最终用户和分销管道划分 - 全球预测（2025-2032 年）

Herpes Marker Testing Market by Test Type, Technology, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，疱疹标记物检测市场规模将成长 8.341 亿美元，复合年增长率为 6.66%。

关键市场统计数据
基准年 2024 4.9786亿美元
预计年份：2025年 5.3176亿美元
预测年份 2032 8.341亿美元
复合年增长率 (%) 6.66%

对疱疹标誌物检测进行策略性概述，重点在于临床效用、诊断途径、技术趋势以及影响决策的相关人员需求。

疱疹病毒标记检测在现代感染疾病诊断中发挥核心作用，它将临床决策与公共卫生监测和以患者为中心的护理联繫起来。血清学和分子检测技术的进步提高了诊断准确性，缩短了检测结果的周转时间，并将检测能力从集中式检查室扩展到了照护现场。临床医师越来越依赖抗体检测结合核酸增幅检查来区分原发性感染、復发性感染和无症状感染。同时，检查室管理者致力于整合能够平衡灵敏度、特异性、成本和通量的工作流程。

分子诊断技术的创新、检测的去中心化、监管政策的变化以及供应链的重组，推动了疱疹诊断领域技术和系统的快速变革。

疱疹诊断领域正经历着变革性的转变，这主要得益于技术的成熟、患者期望的不断变化以及法规结构的调整。分子诊断技术，尤其是日益普及的即时PCR平台，提高了有症状和无症状病例的病毒检测标准，提供了更高的灵敏度和更快的检测结果。同时，血清学检测也日趋完善。免疫检测设计和抗原选择的进步使得急性感染和先前感染的鑑别更加准确，而IgM和IgG结果解读的改进也减少了诊断的不确定性。

2025年美国关税变化对诊断采购、供应商策略和检测途径的营运和供应链影响

2025年美国关税政策对诊断试剂供应商、检查室采购以及疱疹病毒标记检测的获取途径产生了多方面的影响。依赖跨境生产或零件采购的供应商正面临不断上涨的进口成本，且不同产品类型的进口成本差异很大，这给单位定价和库存策略带来了压力。因此，医院实验室和独立诊断网路的采购团队正在重新审查供应商合同，延长库存计划週期，并重新评估标价之外的总到岸成本。

按细分市场分類的诊断趋势：检测类型、检测技术、终端用户环境和通路如何共同决定采用率和临床效用

深入分析市场细分，可以发现检测类型、技术平台、终端用户环境和通路如何共同决定诊断方法的采纳、使用模式和营运影响。联合检测与 HSV-1 或 HSV-2 特异性检测之间的差异会影响临床工作流程和结果解读要求。联合检测提供更广泛的诊断讯息，可以简化初步筛检，而特异性检测则支援有针对性的咨询和管理方案。

各区域（美洲、欧洲、中东和非洲、亚太地区）的测试重点和采用模式将影响准入、检验和分发策略。

区域趋势对不同地区疱疹标记检测的采用、监管和分销产生了显着影响。在美洲，诊断生态系统的特点是融合了综合实验室网路、先进的分子诊断能力，并专注于采用分散式检查模式，以改善服务不足地区的可及性。该地区的监管机构正在逐步协调体外诊断试剂的核准流程，同时保持严格的检验标准，并鼓励製造商投资于特定区域的临床数据和上市后监测。

诊断开发人员、检查室网路和技术供应商之间的竞争与合作策略决定了检测生态系统中的成功因素和伙伴关係模式。

诊断试剂开发人员和检测网路之间的竞争动态正在从以产品为中心的竞争演变为以合作、平台伙伴关係和服务导向差异化为特征的更为复杂的生态系统。领先的检测试剂製造商正在寻求整合硬体、试剂和数位化结果管理的解决方案，从而与医院实验室和独立检测网路建立更紧密的联繫。同时，专注于快速检测和模组化分子平台的敏捷诊断创新者则瞄准了特定的临床需求和照护现场（POC​​）场景，在这些场景中，速度和简便性是推动产品普及的关键因素。

产业领导者面临的实际策略挑战包括：增强供应链韧性、加速临床应用以及建立永续的分销和服务模式

产业领导者应采取一系列协同行动，以增强供应链韧性、加速临床应用，并使产品系列与最终用户需求保持一致。首先，优先考虑供应链透明度和多元化将降低关税衝击和跨境中断的风险。各机构应整理关键组件的来源，评估替代供应商，并制定符合主要机构采购週期的库存管理策略。其次，投资于模组化平台设计和可扩展的检验方案，将有助于在集中式实验室和分散式临床环境中快速部署，从而减少培训和品管方面的阻力。

一项严谨的混合方法研究设计，结合了相关利益者访谈、检查室检验审查、监管综合和情境分析，确保了研究结果的可操作性。

本研究采用稳健的混合方法，对分析结果进行三角验证，以确保其对临床、实验室和商业相关人员的实际意义。主要资料收集包括对实验室主任、采购负责人、临床专家和分销合作伙伴进行结构化访谈，以了解决策标准、采购节奏和实际表现的考量。作为相关人员访谈的补充，检查室检验审查评估了血清学和分子平台的检测性能特征，比较了操作要求、週转时间和工作流程整合需求。

整合诊断趋势、营运要务和策略路径，指导相关人员采用和推广疱疹标记检测解决方案。

总体而言，研究结果凸显了当前诊断环境中检测效能、操作可行性和供应连续性共同决定临床影响和应用的现状。分子和血清学检测技术的进步正在扩大诊断能力，而受政策变化和当地基础设施影响的分销和采购动态则影响实际的检测获取。强调采购来源多元化、投资模组化平台以及开展合作检验的策略性应对措施，能够帮助机构更好地应对临床需求和外部因素带来的干扰。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将人工智慧驱动的预测分析整合到疱疹标记检测结果解读中，以提高诊断准确性
  • 在基层医疗和远端医疗环境中扩大即时疱疹病毒标记筛检的照护现场
  • 开发一种能够同时检测多种疱疹病毒标记和合併感染的多重PCR平台
  • 疱疹病毒 DNA 量的定量 PCR 检测正越来越多地用于指导抗病毒治疗决策。
  • 透过推广家庭检测套组以及与数位化追踪和远端医疗的合作，提高病人参与。
  • 对检验的HSV-1和HSV-2型特异性血清学检测的需求日益增长，这些检测可用于孕妇筛检和新生儿风险评估。
  • 透过实施标准化参考物质和外部品质保证计划，在全球范围内统一疱疹标记检测结果。
  • 基于 CRISPR 的即时诊断检测方法，可在资源匮乏的环境中超灵敏地检测单纯疱疹病毒标记物
  • 诊断公司与研究机构合作开发新型生物标记物，以区分活动性疱疹感染和潜伏性疱疹感染。
  • 新一代疱疹标记物检测的监管核准正在推动市场成长，因为它可以更快地获得检测结果并降低检测极限。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依检测方法分類的疱疹标记检测市场

  • 联合检查
  • HSV-1
  • HSV-2

9. 按技术分類的疱疹标记检测市场

  • ELISA
    • IgG ELISA
    • IgM ELISA
  • PCR
    • 常规PCR
    • 即时PCR
  • 快速检测
    • 横向流动化验
    • 乳胶凝集测试
  • 西方墨点法

第十章 依最终用户分類的疱疹标记检测市场

  • 诊所
    • 一般诊所
    • 专科诊所
  • 诊断检查室
    • 医院检查室
    • 独立检验机构
  • 医院
  • 研究所

第十一章 疱疹标誌物检测市场（依通路划分）

  • 直接竞标
    • 政府竞标
    • 机构竞标
  • 医院药房
  • 网路药房
    • 公司网站
    • 电子商务平台
  • 零售药房

第十二章 各地区疱疹标记检测市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 疱疹标记检测市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国疱疹标记检测市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • F. Hoffmann-La Roche AG
    • Abbott Laboratories
    • Thermo Fisher Scientific Inc.
    • Siemens Healthineers AG
    • Danaher Corporation
    • bioMerieux SA
    • Qiagen NV
    • Becton Dickinson and Company
    • DiaSorin SpA
    • Bio-Rad Laboratories, Inc.
Product Code: MRR-DD0700E81D12

The Herpes Marker Testing Market is projected to grow by USD 834.10 million at a CAGR of 6.66% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 497.86 million
Estimated Year [2025] USD 531.76 million
Forecast Year [2032] USD 834.10 million
CAGR (%) 6.66%

Strategic overview of herpes marker testing emphasizing clinical utility, diagnostic pathways, technological trends, and stakeholder imperatives shaping decision-making

Herpes marker testing occupies a central role in contemporary infectious disease diagnostics, connecting clinical decision-making to public health surveillance and patient-centered care. Advances in serology and molecular assays have refined diagnostic accuracy, reduced turnaround times, and expanded the settings in which testing can be delivered, from centralized laboratory environments to point-of-care contexts. Clinicians increasingly rely on a combination of antibody detection and nucleic acid amplification to differentiate between primary, recurrent, and asymptomatic infections, while laboratory directors focus on integrating workflows that balance sensitivity, specificity, cost, and throughput.

Against this technical backdrop, stakeholders across the diagnostic value chain are navigating competing pressures: rapid technological innovation, shifting reimbursement paradigms, evolving regulatory expectations, and heightened demand for accessible testing. As a result, procurement leaders and product strategists must evaluate not only assay performance characteristics but also supply chain resilience, distribution pathways, and end-user training requirements. Moreover, translational research continues to influence diagnostic guidelines, prompting laboratories to revisit algorithmic approaches to testing and reporting. In this context, the imperative for timely, actionable intelligence is clear: organizations need evidence that illuminates diagnostic performance in real-world settings, clarifies deployment trade-offs, and supports strategic investment in capabilities that deliver clinical and operational value.

Rapid technological and systemic shifts in herpes diagnostics driven by molecular innovation, decentralization of testing, regulatory change, and supply chain realignment

The landscape of herpes diagnostics is undergoing transformative shifts driven by technological maturation, changing patient expectations, and recalibrated regulatory frameworks. Molecular diagnostics, particularly increasingly accessible real-time PCR platforms, have elevated the standard for viral detection in symptomatic and asymptomatic presentations, offering both higher sensitivity and faster turnaround. At the same time, serological assays have become more nuanced; advances in immunoassay design and antigen selection enable better differentiation between acute and past exposure, and the refinement of IgM and IgG interpretation is reducing diagnostic ambiguity.

Simultaneously, decentralization of testing is reshaping care pathways. Point-of-care rapid tests that leverage lateral flow technologies now offer clinicians and community health providers pragmatic tools for immediate decision-making, while digital health integrations facilitate result reporting, patient counseling, and linkage to care. Regulatory bodies in several regions have also adjusted pathways to balance expedited access to novel diagnostics with robust post-market surveillance, prompting manufacturers to invest in data capture and real-world performance studies. Finally, supply chain diversification and strategic partnerships between assay developers, laboratory networks, and distribution platforms are accelerating the translation of innovation into routine clinical use, reinforcing a competitive environment where speed to validation and operational scalability matter as much as analytical performance.

Operational and supply chain consequences of United States tariff changes in 2025 affecting diagnostic procurement, supplier strategies, and access pathways for testing

The tariff measures implemented in the United States in 2025 have created multi-layered implications for diagnostic suppliers, laboratory procurement, and access pathways for herpes marker testing. Suppliers that rely on cross-border manufacturing and component sourcing have encountered elevated import costs that, while varying by product category, have exerted pressure on unit-level pricing and inventory strategies. Consequently, procurement teams in hospital laboratories and independent diagnostic networks have recalibrated supplier contracts, extended inventory planning horizons, and reexamined total landed costs beyond nominal list prices.

Operationally, laboratories have responded by diversifying supplier bases and accelerating evaluation of domestic or near-shore manufacturing alternatives to mitigate tariff exposure. This shift has influenced capital planning, as procurement of automated analyzers and associated consumables now factors in potential tariff-driven lead times and substitution risks. In parallel, distribution channels experienced adjustments: direct tenders and institutional procurement negotiations increasingly incorporate tariff contingencies, while online and retail pharmacy distributors reassessed pricing and margin structures to maintain service continuity.

Clinically, the cumulative effect of tariffs has manifested in constrained purchasing windows for some facilities and a heightened emphasis on assay selection criteria that balance robustness with supply reliability. Regulatory interactions have also intensified as manufacturers submit supplemental documentation to demonstrate equivalent performance for alternate sourcing arrangements. In sum, the 2025 tariff environment has underscored the strategic importance of supply chain transparency, flexible procurement models, and collaborative manufacturer-laboratory planning to sustain diagnostic access and continuity of care.

Segment-specific diagnostic dynamics showing how test types, assay technologies, end-user environments, and distribution channels jointly determine adoption and clinical utility

A nuanced view of segmentation illuminates how test type, technology platform, end-user environment, and distribution channel collectively determine diagnostic adoption, utilization patterns, and operational implications. Test type distinctions between combined assays and assays specific to HSV-1 or HSV-2 influence clinical workflows and interpretation requirements; combined assays offer diagnostic breadth that can streamline initial screening, whereas type-specific assays support targeted counseling and management pathways.

Technology segmentation further alters laboratory and clinical decisions. Enzyme-linked immunosorbent assays present as robust serological options with sub-class distinctions in IgG and IgM testing that inform timing and exposure status, while polymerase chain reaction workflows, differentiated into conventional and real-time PCR, change throughput and reporting cadence. Rapid testing modalities, encompassing lateral flow assays and latex agglutination approaches, enable near-patient diagnostic decisions and reduce time-to-action, and western blot maintains a role as a confirmatory technique in complex serological cases. These technological choices interact with end-user characteristics: general and specialized clinics, hospital laboratories and independent diagnostic labs, and research institutes each have distinct operational capacities, regulatory obligations, and patient case mixes that determine the ideal mix of assays and platforms.

Distribution channels also drive access and procurement strategies. Government and institutional tenders shape large-scale procurement cycles, hospital pharmacies coordinate inventory for inpatient and outpatient services, while online sales via company websites and e-commerce platforms, together with retail pharmacies, broaden patient access and enable alternate purchasing patterns. Taken together, this segmentation underscores the need for differentiated product strategies that account for assay performance, deployment setting, regulatory requirements, and distribution mechanics to optimize clinical impact and operational efficiency.

Regional testing priorities and adoption patterns across the Americas, Europe, Middle East & Africa, and Asia-Pacific shaping access, validation, and distribution strategies

Regional dynamics exert a pronounced influence on the adoption, regulation, and distribution of herpes marker testing across distinct geographies. In the Americas, diagnostic ecosystems are characterized by a mix of consolidated laboratory networks, advanced molecular capacity, and an increasing emphasis on decentralized testing models to improve access in underserved areas. Regulatory agencies in this region are progressively harmonizing pathways for in vitro diagnostics while maintaining rigorous validation standards, which incentivizes manufacturers to invest in region-specific clinical data and post-market surveillance efforts.

In Europe, Middle East & Africa, variability in infrastructure and regulatory maturity creates a heterogeneous landscape in which adoption patterns differ markedly between urban, tertiary centers and peripheral facilities. This region presents significant opportunities for point-of-care technologies to expand reach, while established hospital laboratories continue to anchor confirmatory testing and advanced molecular diagnostics. Stakeholders must navigate diverse reimbursement mechanisms and import regulations, which often necessitates tailored distribution strategies and local partnerships to ensure sustained access.

Asia-Pacific demonstrates rapid uptake of both cutting-edge molecular platforms and scalable serological assays, driven by strong public health initiatives and significant private sector laboratory investment. The combination of large patient volumes, growing laboratory capacity, and proactive regulatory pathways accelerates validation timelines for novel diagnostics, yet it also requires manufacturers to address varied clinical practice patterns and local language and reporting requirements. Across all regions, alignment between technology selection, end-user capabilities, and distribution approaches will determine the success of diagnostic implementations and their impact on patient care.

Competitive and collaborative strategies among diagnostic developers, laboratory networks, and technology providers defining success factors and partnership models in testing ecosystems

Competitive dynamics among diagnostic developers and laboratory networks have evolved from product-centric rivalries to more complex ecosystems featuring collaboration, platform partnerships, and service-oriented differentiation. Leading assay manufacturers increasingly pursue integrated solutions that combine hardware, reagents, and digital result management to create stickier relationships with hospital laboratories and independent testing networks. At the same time, nimble diagnostic innovators focusing on rapid assays or modular molecular platforms target niche clinical needs and point-of-care scenarios where speed and simplicity drive adoption.

Laboratory groups, including hospital laboratories and independent diagnostic providers, are differentiating through consolidated testing menus, quality assurance programs, and value-added reporting that contextualizes serological and molecular results for clinicians. Strategic alliances between manufacturers and distribution partners enhance reach into government tender channels and institutional procurement cycles, while direct-to-provider and online distribution strategies expand patient-facing access. Additionally, partnerships with research institutes facilitate clinical validation studies and support regulatory submissions, enabling faster real-world evidence generation. In this environment, competitive advantage accrues to organizations that combine rigorous analytical performance with supply chain reliability, flexible commercial models, and services that simplify implementation for end users across clinical and community settings.

Practical strategic imperatives for industry leaders to strengthen supply resilience, accelerate clinical adoption, and build sustainable distribution and service models

Industry leaders should pursue a set of coordinated actions that enhance supply resilience, accelerate clinical adoption, and align product portfolios with end-user requirements. First, prioritizing supply chain transparency and diversification will reduce exposure to tariff shocks and cross-border disruptions; organizations should map critical component sourcing, qualify alternate suppliers, and build inventory management strategies that reflect procurement cycles of major institutional buyers. Second, investing in modular platform designs and scalable validation packages will enable faster deployment across both centralized laboratories and decentralized care settings, while reducing the friction associated with training and quality control.

Third, cultivating collaborative relationships with hospital systems, independent laboratories, and research institutes will expedite real-world performance studies and streamline regulatory interactions; these partnerships can also support joint educational initiatives that improve clinician interpretation of serological and molecular results. Fourth, aligning distribution strategies to account for government tenders, institutional purchasing, hospital pharmacy logistics, and e-commerce channels will broaden access while permitting differentiated pricing and service models. Finally, embedding digital result reporting, patient linkage to care pathways, and analytics to monitor post-market performance will create a value proposition that extends beyond the assay itself, supporting sustained uptake and evidence-based refinements to product offerings.

Rigorous mixed-methods research design combining stakeholder interviews, laboratory validation reviews, regulatory synthesis, and scenario mapping to ensure actionable findings

The research employed a robust mixed-methods approach designed to triangulate analytical findings and ensure practical relevance for clinical, laboratory, and commercial stakeholders. Primary data collection included structured interviews with laboratory directors, procurement officials, clinical specialists, and distribution partners to capture decision-making criteria, procurement rhythms, and real-world performance considerations. Complementing stakeholder interviews, laboratory validation reviews evaluated assay performance characteristics across serological and molecular platforms, comparing operational requirements, turnaround times, and workflow integration needs.

Secondary analysis synthesized regulatory documentation, peer-reviewed literature, and clinical guideline updates to contextualize technological changes and interpret implications for deployment. The methodology incorporated scenario mapping to assess supply chain and procurement responses under different policy and operational conditions, and data synthesis prioritized reproducibility and transparency through documented inclusion criteria and analytical procedures. Throughout, findings were cross-checked with subject-matter experts to validate interpretations and ensure recommendations reflect implementable actions in diverse clinical and institutional environments.

Synthesis of diagnostic trends, operational imperatives, and strategic pathways to guide stakeholders as they implement and scale herpes marker testing solutions

In aggregate, the evidence highlights a diagnostic landscape in which assay performance, operational feasibility, and supply continuity jointly determine clinical impact and adoption. Technological advances in molecular and serological testing are expanding diagnostic capabilities, while distribution and procurement dynamics, shaped by policy changes and regional infrastructure, influence actual access to testing. Strategic responses that emphasize diversified sourcing, modular platform investments, and collaborative validation efforts will position organizations to respond to both clinical demand and external disruptions.

Moving forward, stakeholders that integrate rigorous validation, clinician education, and flexible commercial models will realize the greatest clinical and operational returns. The interplay between rapid point-of-care solutions and centralized laboratory confirmatory testing will continue to define diagnostic pathways, and organizations that proactively align product development with end-user workflows and regional regulations will be better prepared to deliver consistent, patient-centered diagnostic services. Ultimately, the path to sustained success lies in balancing innovation with pragmatic implementation strategies that prioritize reliability, interpretability, and equitable access across care settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of AI-driven predictive analytics in herpes marker test interpretation to improve diagnostic accuracy
  • 5.2. Expansion of point-of-care herpes simplex virus marker assays to primary care and telemedicine settings for rapid screening
  • 5.3. Development of multiplex PCR platforms enabling simultaneous detection of multiple herpesvirus markers and co-infections
  • 5.4. Growing adoption of quantitative PCR testing for herpesviral DNA loads to guide antiviral therapy decisions
  • 5.5. Rise of at-home herpes marker testing kits with digital follow-up telehealth integration enhancing patient engagement
  • 5.6. Increase in demand for HSV-1 and HSV-2 type-specific serological assays validated for maternal screening and neonatal risk assessment
  • 5.7. Implementation of standardized reference materials and external quality assurance programs to harmonize herpes marker testing results globally
  • 5.8. Emergence of CRISPR-based point-of-care diagnostic assays offering ultra-sensitive detection of herpes simplex virus markers in low-resource settings
  • 5.9. Partnerships between diagnostic companies and research institutions to develop novel biomarkers differentiating between active and latent herpes infections
  • 5.10. Regulatory approvals of next-generation herpes marker tests with shorter turnaround times and lower limits of detection driving market growth

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Herpes Marker Testing Market, by Test Type

  • 8.1. Combined
  • 8.2. Hsv-1
  • 8.3. Hsv-2

9. Herpes Marker Testing Market, by Technology

  • 9.1. Elisa
    • 9.1.1. Igg Elisa
    • 9.1.2. Igm Elisa
  • 9.2. Pcr
    • 9.2.1. Conventional Pcr
    • 9.2.2. Real-Time Pcr
  • 9.3. Rapid Test
    • 9.3.1. Lateral Flow Assay
    • 9.3.2. Latex Agglutination
  • 9.4. Western Blot

10. Herpes Marker Testing Market, by End User

  • 10.1. Clinics
    • 10.1.1. General Clinics
    • 10.1.2. Specialized Clinics
  • 10.2. Diagnostic Laboratories
    • 10.2.1. Hospital Labs
    • 10.2.2. Independent Laboratories
  • 10.3. Hospitals
  • 10.4. Research Institutes

11. Herpes Marker Testing Market, by Distribution Channel

  • 11.1. Direct Tender
    • 11.1.1. Government Tender
    • 11.1.2. Institutional Tender
  • 11.2. Hospital Pharmacies
  • 11.3. Online Pharmacies
    • 11.3.1. Company Websites
    • 11.3.2. E-Commerce Platforms
  • 11.4. Retail Pharmacies

12. Herpes Marker Testing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Herpes Marker Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Herpes Marker Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. F. Hoffmann-La Roche AG
    • 15.3.2. Abbott Laboratories
    • 15.3.3. Thermo Fisher Scientific Inc.
    • 15.3.4. Siemens Healthineers AG
    • 15.3.5. Danaher Corporation
    • 15.3.6. bioMerieux SA
    • 15.3.7. Qiagen NV
    • 15.3.8. Becton Dickinson and Company
    • 15.3.9. DiaSorin S.p.A.
    • 15.3.10. Bio-Rad Laboratories, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HERPES MARKER TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. HERPES MARKER TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. HERPES MARKER TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HERPES MARKER TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HERPES MARKER TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HERPES MARKER TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY COMBINED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY COMBINED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY COMBINED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY COMBINED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY COMBINED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY COMBINED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HSV-1, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HSV-1, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HSV-1, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HSV-1, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HSV-1, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HSV-1, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HSV-2, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HSV-2, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HSV-2, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HSV-2, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HSV-2, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HSV-2, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY ELISA, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY IGG ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY IGG ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY IGG ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY IGG ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY IGG ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY IGG ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY IGM ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY IGM ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY IGM ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY IGM ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY IGM ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY IGM ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RAPID TEST, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RAPID TEST, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RAPID TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RAPID TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RAPID TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RAPID TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RAPID TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RAPID TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY LATEX AGGLUTINATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY LATEX AGGLUTINATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY LATEX AGGLUTINATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY LATEX AGGLUTINATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY LATEX AGGLUTINATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY LATEX AGGLUTINATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY WESTERN BLOT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY WESTERN BLOT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY WESTERN BLOT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY WESTERN BLOT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY WESTERN BLOT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY WESTERN BLOT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY GENERAL CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY GENERAL CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY GENERAL CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY GENERAL CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY SPECIALIZED CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY SPECIALIZED CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY SPECIALIZED CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY SPECIALIZED CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HOSPITAL LABS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HOSPITAL LABS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HOSPITAL LABS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HOSPITAL LABS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HOSPITAL LABS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HOSPITAL LABS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DIRECT TENDER, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DIRECT TENDER, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DIRECT TENDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DIRECT TENDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DIRECT TENDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DIRECT TENDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DIRECT TENDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY DIRECT TENDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY GOVERNMENT TENDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY GOVERNMENT TENDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY GOVERNMENT TENDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY GOVERNMENT TENDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY GOVERNMENT TENDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY GOVERNMENT TENDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY INSTITUTIONAL TENDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY INSTITUTIONAL TENDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY INSTITUTIONAL TENDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY INSTITUTIONAL TENDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY INSTITUTIONAL TENDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY INSTITUTIONAL TENDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY COMPANY WEBSITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY COMPANY WEBSITES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY COMPANY WEBSITES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY COMPANY WEBSITES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY COMPANY WEBSITES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY COMPANY WEBSITES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY E-COMMERCE PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY E-COMMERCE PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY E-COMMERCE PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY E-COMMERCE PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY E-COMMERCE PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY E-COMMERCE PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL HERPES MARKER TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY ELISA, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY RAPID TEST, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY RAPID TEST, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY DIRECT TENDER, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY DIRECT TENDER, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS HERPES MARKER TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY ELISA, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY RAPID TEST, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY RAPID TEST, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY DIRECT TENDER, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY DIRECT TENDER, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA HERPES MARKER TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY ELISA, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY RAPID TEST, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY RAPID TEST, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY DIRECT TENDER, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY DIRECT TENDER, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA HERPES MARKER TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY ELISA, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY RAPID TEST, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY RAPID TEST, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY DIRECT TENDER, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY DIRECT TENDER, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA HERPES MARKER TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE HERPES MARKER TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE HERPES MARKER TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE HERPES MARKER TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE HERPES MARKER TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE HERPES MARKER TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE HERPES MARKER TESTING MARKET SIZE, BY ELISA, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE HERPES MARKER TESTING MARKET SIZE, BY ELISA, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE HERPES MARKER TESTING MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE HERPES MARKER TESTING MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE HERPES MARKER TESTING MARKET SIZE, BY RAPID TEST, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE HERPES MARKER TESTING MARKET SIZE, BY RAPID TEST, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE HERPES MARKER TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE HERPES MARKER TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE HERPES MARKER TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPE HERPES MARKER TESTING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPE HERPES MARKER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPE HERPES MARKER TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPE HERPES MARKER TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPE HERPES MARKER TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPE HERPES MARKER TESTING MARKET SIZE, BY DIRECT TENDER, 2018-2024 (USD MILLION)